Poster Infektionen der Haut P 27 Identification of HPV vaccine-genotypes in a female STI population group Natalie Isabella Hartl 1 Claudia Heller-Vitouch 1 Angelika Stary 1 1 Outpatients Centre for STD Diagnosis, Vienna, Austria Background and Objectives: Women harbouring HPV genotypes are at risk to develop either genital warts or cervical dysplasia as a precursor of cervical carcinoma. Aim of the study was to evaluate the prevalence of HPV vaccine-genotypes in a symptomatic and asympytomatic female population group. Furthermore, an age-related distribution of different genotypes was investigated for different clinical syndromes. Materials and Methods: Data were collected from 4230 patients between February and July <strong>2012</strong>. Material was either delivered or sent to the Outpatients Centre laboratory or sampled and processed at the Outpatients Centre. Clinical diagnosis was assessed by the referring physician. Samples were collected either from the cervical area or from genital lesions by Cytobrush DNAPAP Cervical Sampler. Viral DNA detection and HPV genotyping was performed using Papillo Check PCR. Data from women with the diagnosis of cervical dysplasia and cervical cancer precursors including PAP III, IIID, IV and CIN I, II, III (n= 1485) and genital warts, respectively, were included. Additionally, data were evaluated according to age groups of women from 20 to 30 and 50 to 60 years. Results: Out of all 1485 patients with cervical dysplasia and cervical cancer precursors 55,2% were HPV high-risk positive. In 29.5% infection with HPV 16, and in 6.1%, respectively, HPV 18 could be detected. Furthermore, referring to vaccination cross immunity HPV 31, 33, 45, and 52 were detected in 14,9% 7,7% , 2,9% and 6,2% respectively. When focusing on the younger age group, 3<strong>2.</strong>9% of all high risk positive patients with cervical dysplasia and cervical cancer precursors turned out to be positive for HPV 16, and 7.8% for HPV 18. Other frequently detected HPV high-risk types in this age group were HPV 31 (14%), HPV 45 (1,9%), HPV 51 (19,2%) and HPV 56 (9,3%). In contrast to these results, in women between 50 and 60 years of age with cervical dysplasia and cervical cancer precursors an infection with HPV 16 was detected only in 20%, with HPV 18 in 4% and with HPV 45 in 6%, respectively. In addition, HPV 51 was detected in 12% and HPV 56 in 18%. The identification of genotypes evaluated for different age groups shows that both strains, HPV 16 and 18, were more often detected in young women and decreased with increasing age. In contrast, an increase of HPV high-risk types other than 16 and 18, such as HPV 45 and 56, were more often identified in older women. In the group of individuals with genital warts (n=558), HPV-low-risk types were detected in 4<strong>2.</strong>8%. The genotyping showed a higher detection rate of HPV 6 (60,7%) compared with HPV 11 (10.5%). Conclusion: A high number of the HPV high-risk types 16 and 18 was detected especially in the group of young women compared with women in the higher age 74
Poster Infektionen der Haut group. It can therefore be considered that vaccination in the young female population would have prevented HPV dependent cervical dysplastic lesions in at least 35.6% of cases. In case of using the quadrivalent vaccine in our study cohort genital warts would have been prevented in 71.2% of cases. 75